API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).
Lead Product(s): VLX-1005
Therapeutic Area: Hematology Product Name: VLX-1005
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hatteras Venture
Deal Size: $16.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2021